Qiagen (NYSE:QGEN) Shares Set to Reverse Split on Thursday, January 8th

Shares of Qiagen N.V. (NYSE:QGEN) are going to reverse split on Thursday, January 8th. The 19-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, January 7th.

Qiagen Stock Down 0.6%

QGEN opened at $45.33 on Wednesday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 2.30 and a current ratio of 2.60. Qiagen has a fifty-two week low of $37.63 and a fifty-two week high of $51.88. The stock has a fifty day moving average of $45.98 and a 200-day moving average of $47.09. The company has a market capitalization of $10.08 billion, a P/E ratio of 24.64, a P/E/G ratio of 2.33 and a beta of 0.68.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.03. The business had revenue of $532.58 million during the quarter, compared to the consensus estimate of $525.68 million. Qiagen had a return on equity of 14.80% and a net margin of 19.58%.Qiagen’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.57 earnings per share. On average, equities analysts expect that Qiagen will post 2.26 EPS for the current year.

Analyst Upgrades and Downgrades

QGEN has been the topic of several recent analyst reports. Wall Street Zen raised Qiagen from a “hold” rating to a “buy” rating in a research note on Sunday, December 21st. Citigroup cut shares of Qiagen from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $55.00 to $50.00 in a research report on Thursday, December 11th. Weiss Ratings reiterated a “hold (c)” rating on shares of Qiagen in a research note on Monday. Finally, Barclays reissued an “overweight” rating and issued a $55.00 price target (up from $53.00) on shares of Qiagen in a report on Monday, December 15th. Two analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $49.61.

Institutional Trading of Qiagen

Hedge funds have recently modified their holdings of the company. Allworth Financial LP lifted its position in Qiagen by 23.2% during the 3rd quarter. Allworth Financial LP now owns 1,358 shares of the company’s stock valued at $61,000 after purchasing an additional 256 shares during the period. Danske Bank A S bought a new stake in shares of Qiagen during the 3rd quarter valued at $36,000. Advisory Services Network LLC acquired a new position in shares of Qiagen in the 3rd quarter valued at $64,000. Dark Forest Capital Management LP bought a new position in shares of Qiagen in the 3rd quarter worth $283,000. Finally, XTX Topco Ltd bought a new position in shares of Qiagen in the 3rd quarter worth $749,000. Institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.